Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term
Share This

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Latest Mizuho News

Mizuho Americas wins five FCS Portfolio Awards

Mizuho Americas wins five FCS Portfolio Awards

May 20, 2026
Mizuho Head of Investment: AI is imacting every sector in the global economy

Mizuho Head of Investment: AI is imacting every sector in the global economy

June 9, 2026
Graig Suvannavejh: ASCO is one of the highlights of our year in biotech

Graig Suvannavejh: ASCO is one of the highlights of our year in biotech

May 29, 2026

Mizuho news from around the globe

back-to-top-blue